PE 22-28 Research Guide

Full name: PE 22-28 (Spadin-Derived TREK-1 Peptide)

A synthetic peptide derived from spadin that blocks the TREK-1 potassium channel, researched as a fast-acting antidepressant and neuroplasticity agent. Biohackers track it for mood, neurogenesis, and stroke-recovery research; it remains preclinical.

How PE 22-28 Works

Selectively blocks the TREK-1 background potassium channel. TREK-1 inhibition enhances serotonergic signaling and rapidly increases synaptogenesis and neurogenesis, producing antidepressant-like effects faster than SSRIs in animal models.

Dosing Protocol

• Typical dose: Not established for humans
• Frequency: Research only
• Duration: Research only
• Route: Intranasal or injection (research)

Reported Benefits

• Rapid antidepressant effects (preclinical)
• Promotes neurogenesis and synaptogenesis
• TREK-1 channel blockade
• Neuroplasticity research interest

Potential Side Effects

• Unknown human safety
• No approved human use
• Unproven efficacy in humans

Research Citations

1. PE 22-28 and TREK-1 antidepressant effects (2017) - The spadin analog PE 22-28 blocked TREK-1 and produced rapid antidepressant and neurogenic effects in rodent models.

Related Cognitive & Nootropic Compounds

• Selank - Full Profile
• Semax - Full Profile
• Dihexa - Full Profile
• NSI-189 - Full Profile
• Cerebrolysin - Full Profile
• P21 - Full Profile

View full PE 22-28 profile with 3D molecule viewer →